Identification and Description of Patients With High-risk Non Metastatic RCC
ConditionRenal Cell Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions
Eligibility criteria
Qualifiers
Adult patients diagnosed with local RCC or high-risk locally advanced RCC,
Included in UroCCR register between 1st january 2014 and 31st december 2023,
Consenting to participate in UroCCR and UroCCR-Chain registers.
Disqualifiers
Patients with metastatic disease at inclusion,
Patients not linked between UroCCR and SNDS datasources,
Patients with hereditary RCC.
Trial design
Treatments tested in this trial
- Cohort 1
- Cohort 2
- Cohort 3
Treatment groups
6,109 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov